Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 1.00 |
| ▸ | JAK3 | P52333 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.83 |
| ▸ | SYK | P43405 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifidancitinib SCHEMBL342002 | 1.00 | JAK1 (1.00) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29609558 | 1.00 | JAK1 (1.00) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL20767498 | 0.99 | JAK1 (0.98) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29358204 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL29358557 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL525194 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL525310 | 0.96 | JAK1 (0.92) | JAK1JAK3JAK2CYP1A2TYK2 | |
| Ifidancitinib SCHEMBL23356291 | 0.95 | JAK1 (0.90) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL23356183 | 0.94 | JAK1 (0.88) | JAK1JAK3JAK2CYP1A2TYK2 | |
| SCHEMBL339570 | 0.94 | JAK1 (0.88) | JAK1JAK3JAK2CYP1A2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | claimed |
| US-20250367113-A1 | DRUG DELIVERY SYSTEM COMPRISING AN ANTI-INFLAMMATORY AGENT OR A SALT THEREOF FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-12-04 | — | — | US | claimed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| CN-119325375-A | Drug delivery system comprising an anti-inflammatory agent or a salt thereof for application to the esophageal mucosa | 伊斯凯普公司 | 2025-01-17 | — | — | CN | claimed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| CN-118715226-A | Compounds and uses thereof | 上海岸阔医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240139327-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | MINGHUI PHARMACEUTICAL (HANGZHOU) LIMITED (CN) | 2024-05-02 | — | — | US | claimed |
| EP-4293020-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Minghui Pharmaceutical (Hangzhou) Limited (CN) | 2023-12-20 | — | — | EP | claimed |
| WO-2023237425-A1 | DRUG DELIVERY SYSTEM COMPRISING AN ANTI-INFLAMMATORY AGENT OR A SALT THEREOF FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | claimed |
| US-20230293503-A1 | USE OF BERBERINE ANALOG AND JAK INHIBITOR IN TREATMENT OF INFLAMMATORY DISEASES OF GASTROINTESTINAL TRACT | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | claimed |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | claimed |
| WO-2023155905-A1 | COMPOUND AND USE THEREOF | 上海岸阔医药科技有限公司 | 2023-08-24 | — | — | WO | claimed |
| US-20230233158-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | PFIZER INC. (US) | 2023-07-27 | — | — | US | claimed |
| CN-116249533-A | Intestinal tract cracking type co-drug and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2023-06-09 | — | — | CN | claimed |
| EP-4186900-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | Ennovabio (Zhejiang) Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | claimed |
| EP-4167838-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | Pfizer Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| CN-116018653-A | Computerized decision support tool and medical device for scratch detection and seizure prediction | 辉瑞公司 | 2023-04-25 | — | — | CN | claimed |
| WO-2022171140-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-08-18 | — | — | WO | claimed |
| CN-114907353-A | Prodrug compound and preparation method and application thereof | 明慧医药（杭州）有限公司 | 2022-08-16 | — | — | CN | claimed |
| EP-4167838-B1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | PFIZER (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | SEAPORT THERAPEUTICS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12498382-B2 | Biomarkers for vitiligo | INCYTE CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250367113-A1 | DRUG DELIVERY SYSTEM COMPRISING AN ANTI-INFLAMMATORY AGENT OR A SALT THEREOF FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-12-04 | — | — | US | disclosed |
| WO-2025226637-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | INCYTE CORPORATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4590700-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | Novocure GmbH (CH) | 2025-07-30 | — | — | EP | disclosed |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4570321-A2 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | Incyte Corporation (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | disclosed |
| WO-2025121754-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SKIN DISEASES COMPRISING JANUS KINASE INHIBITOR | 장병모 | 2025-06-12 | — | — | WO | disclosed |
| US-12280054-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | INCYTE CORPORATION (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4255442-B1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORP (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250049817-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORP (US) | 2025-02-13 | — | — | US | disclosed |
| US-12203942-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| CN-119325375-A | Drug delivery system comprising an anti-inflammatory agent or a salt thereof for application to the esophageal mucosa | 伊斯凯普公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20240390378-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | INCYTE CORPORATION | 2024-11-28 | — | — | US | disclosed |
| CN-118715226-A | Compounds and uses thereof | 上海岸阔医药科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12099068-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2024-09-24 | — | — | US | disclosed |
| EP-4424328-A2 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | Incyte Corporation (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-12005067-B2 | JAK inhibitor with a vitamin D analog for treatment of skin diseases | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-11992490-B2 | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) | INCYTE CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240139327-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | MINGHUI PHARMACEUTICAL (HANGZHOU) LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | PFIZER INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-115361974-B | Use of berberine analogues and JAK inhibitors in the treatment of inflammatory diseases of the gastrointestinal tract | 轶诺(浙江)药业有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024062457-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | NOVOCURE GMBH (CH) | 2024-03-28 | — | — | WO | disclosed |
| US-20240101661-A1 | TREATING SKIN IRRITATION FROM APPLICATION OF AN ALTERNATING ELECTRIC FIELD | NOVOCURE GMBH (CH) | 2024-03-28 | — | — | US | disclosed |
| EP-4293020-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Minghui Pharmaceutical (Hangzhou) Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023237425-A1 | DRUG DELIVERY SYSTEM COMPRISING AN ANTI-INFLAMMATORY AGENT OR A SALT THEREOF FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117157080-A | JAK inhibitors containing vitamin D analogues for the treatment of skin disorders | 因赛特公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-4263526-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4263538-A1 | PYRIDO[2,3-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TEATMENT OF SKIN DISEASE | Pfizer Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4255442-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | Incyte Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230293503-A1 | USE OF BERBERINE ANALOG AND JAK INHIBITOR IN TREATMENT OF INFLAMMATORY DISEASES OF GASTROINTESTINAL TRACT | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230280220-A1 | Benzimidazole Derivative Compounds and Uses Thereof | PFIZER INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2023155905-A1 | COMPOUND AND USE THEREOF | 上海岸阔医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-20230233158-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | PFIZER INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230220478-A1 | BIOMARKERS FOR VITILIGO | INCYTE CORPORATION | 2023-07-13 | — | — | US | disclosed |
| CN-116249533-A | Intestinal tract cracking type co-drug and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4186900-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | Ennovabio (Zhejiang) Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | PFIZER INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4167838-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | Pfizer Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-116018653-A | Computerized decision support tool and medical device for scratch detection and seizure prediction | 辉瑞公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11624751-B2 | Biomarkers for vitiligo | INCYTE CORPORATION (US) | 2023-04-11 | — | — | US | disclosed |
| CN-112533606-B | Application of JAK kinase inhibitor and EGFR inhibitor in preparation of medicines for treating tumor diseases | 江苏恒瑞医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11584961-B2 | Biomarkers for inflammatory skin disease | INCYTE CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | INCYTE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PFIZER INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-4077316-A1 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022171140-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 明慧医药（杭州）有限公司 | 2022-08-18 | — | — | WO | disclosed |
| CN-114907353-A | Prodrug compound and preparation method and application thereof | 明慧医药（杭州）有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-111094314-B | Prodrug containing glucuronide derivative JAK inhibitor and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220241286-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | INCYTE CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION | 2022-06-30 | — | — | US | disclosed |
| US-11372003-B2 | Biomarkers for graft-versus-host disease | INCYTE CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022130175-A1 | PYRIDO[2,3-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TEATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022130171-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF ITK FOR THE TREATMENT OF SKIN DISEASE | PFIZER INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022120131-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | INCYTE CORPORATION (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | INCYTE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3941474-A2 | BIOMARKERS FOR VITILIGO | Incyte Corporation (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3941474-A2 | BIOMARKERS FOR VITILIGO | Incyte Corporation (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559538-B2 | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | PDE4B, PDE4A, PDE3B | JAK1 2263/4885JAK3 2865/4885JAK2 2446/4885 |
| US-12005067-B2 | JAK inhibitor with a vitamin D analog for treatment of skin diseases | JAK3, IL23R, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 5/4885 |
| US-11372003-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK1 5/4885JAK3 4/4885JAK2 26/4885 |
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-11304949-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-20240132477-A1 | Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease | ITK, BLK, BCKDK | JAK1 59/4885JAK3 125/4885JAK2 208/4885 |
| US-20240390378-A1 | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND LICHEN PLANUS (LP) | JAK1, JAK3, JAK2 | JAK1 1/4885JAK3 2/4885JAK2 3/4885 |
| US-12360120-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK1 7/4885JAK3 6/4885JAK2 38/4885 |
| US-12498382-B2 | Biomarkers for vitiligo | TSG101, JAK3, IFNG | JAK1 5/4885JAK3 2/4885JAK2 13/4885 |
| US-20240139327-A1 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, NOTUM | JAK1 3194/4885JAK3 4246/4885JAK2 4085/4885 |
| US-20260021096-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-20250325664-A1 | COMBINATION THERAPY WITH AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY AND A JAK INHIBITOR | JAK1, CSF3R, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 5/4885 |
| US-20220241286-A1 | TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-20250049817-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | JAK3, IL23R, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 5/4885 |
| US-12099068-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK1 5/4885JAK3 4/4885JAK2 26/4885 |
| US-20230148402-A1 | Boron Containing PDE4 Inhibitors | PDE4B, PDE4A, PDE3B | JAK1 1657/4885JAK3 1949/4885JAK2 1684/4885 |
| US-20230293503-A1 | USE OF BERBERINE ANALOG AND JAK INHIBITOR IN TREATMENT OF INFLAMMATORY DISEASES OF GASTROINTESTINAL TRACT | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | IRAK4, JAK1, VIP | JAK1 2/4885JAK3 14/4885JAK2 26/4885 |
| US-11624751-B2 | Biomarkers for vitiligo | TSG101, JAK3, IFNG | JAK1 5/4885JAK3 2/4885JAK2 13/4885 |
| US-20220202834-A1 | JAK INHIBITOR WITH A VITAMIN D ANALOG FOR TREATMENT OF SKIN DISEASES | JAK3, IL23R, JAK1 | JAK1 3/4885JAK3 1/4885JAK2 5/4885 |
| US-20240124439-A1 | Pyrido[2,3-D]Imidazole Derivatives and Their Use As Inhibitors of ITK for the Treatment of Skin Disease | ITK, PDXK, HRH4 | JAK1 162/4885JAK3 134/4885JAK2 660/4885 |
| US-11661419-B2 | Benzimidazole derivative compounds and uses thereof | ITK, HRH4, BLK | JAK1 93/4885JAK3 189/4885JAK2 173/4885 |
| US-12594339-B2 | Lipid prodrugs of JAK inhibitors and uses thereof | JAK1, JAK3, JAK2 | JAK1 1/4885JAK3 2/4885JAK2 3/4885 |
| US-20230271982-A1 | CODRUG THAT DISINTEGRATES IN INTESTINE, PREPARATION THEREFOR, AND USE THEREOF | VIP, SI, PDCD5 | JAK1 2922/4885JAK3 3340/4885JAK2 4173/4885 |
| US-12203942-B2 | Biomarkers for graft-versus-host disease | CD74, HLA-DRB1, TSG101 | JAK1 7/4885JAK3 6/4885JAK2 38/4885 |
| US-12280054-B2 | Treatment of hidradenitis suppurativa using JAK inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885JAK3 3/4885JAK2 2/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | JAK1 3705/4885JAK3 4037/4885JAK2 1497/4885 |
| US-11992490-B2 | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) | JAK1, JAK3, JAK2 | JAK1 1/4885JAK3 2/4885JAK2 3/4885 |
| US-20230027606-A1 | BIOMARKERS FOR GRAFT-VERSUS-HOST DISEASE | CD74, HLA-DRB1, TSG101 | JAK1 5/4885JAK3 4/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.